HealthTab™ Goes National: NHS England Backs Avricore's Pharmacy Cholesterol Testing
AVCRF is trading near its 52-week low of $0.001 (0.0% above the low) on light trading volume (0.3× avg).
Summary
NHS England will expand Avricore Health's HealthTab™-powered cholesterol testing programme nationally across England, starting with approximately 100 pharmacies this fall.
Key Events · M&A and Partnerships · AVCRF
-
NHS England Confirms National Expansion
NHS England confirmed the national expansion of the Barts Health pharmacy cholesterol testing programme powered by Avricore's HealthTab™ platform, with approximately 100 pharmacies across England beginning seven-minute cholesterol checks this fall.
-
Pilot Programme Demonstrated Clinical Impact
The north London pilot tested 2,493 patients across 61 community pharmacies between January 2025 and March 2026, identifying 19% as high risk for heart attack or stroke within a decade, with at least 88 patients subsequently beginning statin therapy.
-
First National Phase Runs Until Spring 2027
The first national phase of the NHS initiative will run until spring 2027, providing a multi-year revenue runway for HealthTab™ deployments across England.
-
Follows Abbott Collaboration Announced September 16
This national expansion follows the September 16, 2026 announcement of a multi-year collaboration with Abbott to distribute point-of-care testing products in UK pharmacies, reinforcing the company's UK growth strategy.
Analysis · AVCRF · Life Sciences
A major commercial validation has arrived for Avricore Health, a micro-cap trading near its 52-week low. NHS England confirmed a national rollout of the Barts Health pharmacy cholesterol testing programme powered by Avricore's HealthTab™ platform. Approximately 100 pharmacies will begin offering seven-minute cholesterol checks this fall, with the first national phase running until spring 2027. This follows the September 16 Abbott collaboration announcement, suggesting the UK point-of-care testing strategy is gaining real traction.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVCRF was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $0.00 to $0.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.